AU2021279277A1 - Treatment of cardiometabolic disease with inhibitors of type I interferon signalling - Google Patents

Treatment of cardiometabolic disease with inhibitors of type I interferon signalling Download PDF

Info

Publication number
AU2021279277A1
AU2021279277A1 AU2021279277A AU2021279277A AU2021279277A1 AU 2021279277 A1 AU2021279277 A1 AU 2021279277A1 AU 2021279277 A AU2021279277 A AU 2021279277A AU 2021279277 A AU2021279277 A AU 2021279277A AU 2021279277 A1 AU2021279277 A1 AU 2021279277A1
Authority
AU
Australia
Prior art keywords
ifn
patient
type
patients
anifrolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021279277A
Other languages
English (en)
Inventor
Kerry CASEY
Gabor Illei
Dominic SINIBALDI
Michael Smith
Wendy White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2021279277A1 publication Critical patent/AU2021279277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021279277A 2020-05-29 2021-05-28 Treatment of cardiometabolic disease with inhibitors of type I interferon signalling Abandoned AU2021279277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
US63/031,854 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (1)

Publication Number Publication Date
AU2021279277A1 true AU2021279277A1 (en) 2023-02-02

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021279277A Abandoned AU2021279277A1 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease with inhibitors of type I interferon signalling

Country Status (10)

Country Link
US (1) US12410254B2 (cg-RX-API-DMAC10.html)
EP (2) EP4157873A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023527054A (cg-RX-API-DMAC10.html)
KR (1) KR20230018446A (cg-RX-API-DMAC10.html)
CN (1) CN115667309A (cg-RX-API-DMAC10.html)
AU (1) AU2021279277A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022023438A2 (cg-RX-API-DMAC10.html)
CA (1) CA3183611A1 (cg-RX-API-DMAC10.html)
IL (1) IL298299A (cg-RX-API-DMAC10.html)
WO (1) WO2021239928A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
TW202317617A (zh) * 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
SG11202101946YA (en) * 2018-09-18 2021-04-29 I Mab Biopharma Hangzhou Co Ltd Anti-ifnar1 antibodies for treating autoimmune diseases
EP3881233A4 (en) * 2018-11-15 2022-11-23 Ampel Biosolutions, LLC DISEASE PREDICTION AND TREATMENT PRIORIZATION WITH MACHINE LEARNING

Also Published As

Publication number Publication date
BR112022023438A2 (pt) 2022-12-20
WO2021239928A3 (en) 2022-01-27
KR20230018446A (ko) 2023-02-07
WO2021239928A2 (en) 2021-12-02
CA3183611A1 (en) 2021-12-02
CN115667309A (zh) 2023-01-31
IL298299A (en) 2023-01-01
US20240158519A1 (en) 2024-05-16
EP4566667A3 (en) 2025-09-03
JP2023527054A (ja) 2023-06-26
WO2021239928A9 (en) 2022-03-17
EP4566667A2 (en) 2025-06-11
EP4157873A2 (en) 2023-04-05
US12410254B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
WO2021239928A2 (en) Treatment of cardiometabolic disease
JP6306588B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JP2025131730A (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
EP4114465B1 (en) Anti-ifnar1 dosing regime for subcutaneous injection
Rommer et al. Monoclonal antibodies in treatment of multiple sclerosis
Feldman et al. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy
JP2018500276A (ja) 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
JP2023546361A (ja) ループスにおける紅斑の治療
JP7746407B2 (ja) 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療
WO2021250533A1 (en) Methods of treatment using omalizumab or ligelizumab
TW202317617A (zh) 皮膚紅斑狼瘡之治療
JP7475011B2 (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
WO2022238479A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
TW202332693A (zh) 狼瘡之治療
IL324676A (en) Lupus treatment
JP6923594B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
Rizvi Disease-Modifying Agents
TW202430212A (zh) 狼瘡之治療
WU et al. MMP-2, MMP-9 production was significantly elevated by fibroblast cells isolated from rheumatoid arthritis patient when co-cultured with monocyte (THP-1) with high levels of CD147

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted